Reuters logo
BRIEF-Zealand Pharma royalty revenue of DKK 5.3 mln in Q4 on sales of Lyxumia
February 8, 2017 / 6:58 AM / 8 months ago

BRIEF-Zealand Pharma royalty revenue of DKK 5.3 mln in Q4 on sales of Lyxumia

Feb 8 (Reuters) - Zealand Pharma A/S:

* Royalty revenue from Sanofi’s sales of Lyxumia (lixisenatide) outside the United states of 5.3 million Danish crowns ($760,849)/0.7 million euros ($747,040.00) for Q4 2016

* Annual royalty revenue in respect of lyxumia amounted to 24.3 million crowns/3.3 million euros in 2016 Source text for Eikon: Further company coverage: ($1 = 0.9370 euros) ($1 = 6.9659 Danish crowns) (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below